Loading…
Insight Molecular Diagnostics Inc. is projected to decline to $6.32 by 2027, a -1% move from its current price of $6.41. IMDX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.01 | $6.41 | $6.83 | 0.00% |
| May 30 | $5.86 | $6.41 | $7.02 | -0.01% |
| May 31 | $5.74 | $6.41 | $7.16 | -0.01% |
| Jun 1 | $5.64 | $6.41 | $7.28 | -0.01% |
| Jun 2 | $5.55 | $6.41 | $7.40 | -0.01% |
| Jun 3 | $5.48 | $6.41 | $7.50 | -0.02% |
| Jun 4 | $5.41 | $6.41 | $7.59 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.41 | $6.41 | $7.59 | -0.02% |
| Week 2 | $5.04 | $6.41 | $8.14 | -0.04% |
| Week 3 | $4.78 | $6.41 | $8.59 | -0.05% |
| Week 4 | $4.57 | $6.41 | $8.99 | -0.07% |
| Week 5 | $4.39 | $6.40 | $9.35 | -0.09% |
| Week 6 | $4.23 | $6.40 | $9.69 | -0.11% |
| Week 7 | $4.09 | $6.40 | $10.02 | -0.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
Incorporated in 2009 and based in Nashville, Tennessee, it was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. It has a collaboration agreement with Bio-Rad Laboratories, Inc.
for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company is developing DetermaCNI and DetermaIO, and offers GraftAssureCore, GraftAssureIQ, and GraftAssureDx along with testing services for biomarker discovery, assay design and development, and clinical trial support.
Insight Molecular Diagnostics Inc. (IMDX) is a healthcare stock with current price $6.09 and a market cap of $196.65M, ranking 3859 by market capitalization. The near-term price action sits within a landscape of moderate momentum and a defined range around a bullish trend, reflecting a niche diagnostic services and test development business.
The forecast projects a multi-year path with rising averages and meaningful upside. For 2026 the avg is $6.09 with a min of $2.55 and a max of $9.54 (ROI 0, sentiment NEUTRAL), and the trend accelerates to higher levels by 2030 with an avg of $11.63 and a max of $20.29 (ROI 91, sentiment BULLISH). By 2050 the avg is $55.36 with a max of $127.34 (ROI 809.1, sentiment BULLISH).
A major floor 62.5% below — a decisive break under it would weaken the trend.
The nearest floor, 46.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.5% away) — a breakout level to watch.
A major ceiling 31.7% above — clearing it would confirm fresh momentum.
Key IMDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.20 | Buy | $6.23 | Buy |
| MA 10 | $6.08 | Buy | $5.98 | Buy |
| MA 20 | $5.38 | Buy | $5.49 | Buy |
| MA 50 | $4.35 | Buy | $4.98 | Buy |
| MA 100 | $5.29 | Buy | $4.98 | Buy |
| MA 200 | $4.96 | Buy | $4.78 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.92 | Neutral |
| Stoch RSI (14) | 41.06 | Neutral |
| CCI (20) | 93.64 | Neutral |
| Williams %R (14) | -1.96 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 27.94 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 98.04 | Sell |
| TRIX (15) | 1.74 | Buy |
| Awesome (5,34) | 1.56 | Buy |
| Ultimate (7,14,28) | 57.10 | Neutral |
| Momentum (10) | 1.43 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 6.30 | Buy |
| ADX (14) | 22.74 | Buy |
| ATR (14) | 0.32 | Info |
The near-term technical picture shows bullish momentum. RSI14 is 60, with the 50-day simple moving average at $4.28 and the 200-day simple moving average at $4.92, suggesting price support around the mid-$4s with upside potential toward the near-term resistance at $6.42.
The stock trades within a 30-day range from $3.91 to $9.48, and has an explicit near-term support at $3.00 while facing resistance at $6.42. Annualized volatility is high at 100%, signaling elevated move potential in the weeks ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.55 | $6.41 | $10.21 | 0% | Neutral | |
| $4.55 | $6.32 | $9.51 | -1% | Neutral | |
| $5.41 | $7.98 | $12.75 | +24% | Bullish | |
| $7.98 | $12.38 | $20.75 | +93% | Bullish | |
| $8.50 | $13.82 | $24.09 | +116% | Bullish | |
| $9.19 | $15.61 | $28.16 | +144% | Bullish | |
| $9.12 | $16.17 | $30.05 | +152% | Bullish | |
| $8.32 | $15.36 | $29.33 | +140% | Bullish | |
| $9.08 | $17.43 | $34.13 | +172% | Bullish | |
| $11.27 | $22.49 | $45.05 | +251% | Bullish | |
| $13.09 | $29.10 | $64.00 | +354% | Bullish | |
| $33.59 | $74.64 | $171.67 | +10.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.55 | $6.41 | $7.62 | +0.00% |
| June 2026 | $5.22 | $6.26 | $7.78 | -2.35% |
| July 2026 | $5.24 | $6.40 | $8.15 | +2.17% |
| August 2026 | $5.71 | $7.06 | $9.17 | +10.33% |
| September 2026 | $5.80 | $7.25 | $9.57 | +2.80% |
| October 2026 | $5.55 | $7.00 | $9.37 | -3.48% |
| November 2026 | $5.64 | $7.18 | $9.73 | +2.57% |
| December 2026 | $5.80 | $7.45 | $10.21 | +3.74% |
Click any year to see its month-by-month IMDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMDX is projected to trade between $2.55 and $10.21, averaging $6.41 — a potential gain of 0% from today's $6.41. A consolidation phase looks the most probable path here.
Insight Molecular Diagnostics Inc.'s 2027 outlook centres on $6.32, within a $4.55 to $9.51 range. That is -1% versus the projected 2026 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2028, IMDX could reach as high as $12.75, with a base case around $7.98 and support toward $5.41 — roughly +24% from $6.41. Buyers look set to stay in control over this stretch.
Expect IMDX to range from $7.98 to $20.75 through 2029. The $12.38 average target implies a +93% move from current prices. That is up +55% on the projected 2028 average. Momentum favours further upside here.
The IMDX price prediction for 2030 points to an average of $13.82 (low $8.50, high $24.09) — a potential gain of +116% on today's $6.41. Buyers look set to stay in control over this stretch.
In 2031, IMDX is projected to trade between $9.19 and $28.16, averaging $15.61 — a potential gain of +144% from today's $6.41. That is up +13% on the projected 2030 average. Momentum favours further upside here.
Insight Molecular Diagnostics Inc.'s 2032 outlook centres on $16.17, within a $9.12 to $30.05 range. That is up +4% on the projected 2031 average. That marks a +152% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, IMDX could reach as high as $29.33, with a base case around $15.36 and support toward $8.32 — roughly +140% from $6.41. Momentum favours further upside here.
Expect IMDX to range from $9.08 to $34.13 through 2034. The $17.43 average target implies a +172% move from current prices. That is up +14% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The IMDX price prediction for 2035 points to an average of $22.49 (low $11.27, high $45.05) — a potential gain of +251% on today's $6.41. Momentum favours further upside here.
In 2040, IMDX is projected to trade between $13.09 and $64.00, averaging $29.10 — a potential gain of +354% from today's $6.41. That is up +29% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Insight Molecular Diagnostics Inc.'s 2050 outlook centres on $74.64, within a $33.59 to $171.67 range. That is up +157% on the projected 2040 average. That marks a +10.6x change versus current levels. Momentum favours further upside here.
Investing $1,000 in IMDX today (≈ 156.00624 IMDX) could be worth
$11,644.29
+$10,644.29 (+1064%) by 2050 · US Dollar
Based on the average projected IMDX price of $74.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMDXwould be worth at today's price.
$1,000 invested in IMDX on May 27, 2025 (≈ 307.692308 IMDX) would be worth
$1,972.31
+$972.31 (+97.2%) today · 1.97× · US Dollar
Based on a IMDX entry price of $3.25 vs. today's $6.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.19 | $1,035.54 | +3.6% |
| 1 month ago | $3.84 | $1,669.27 | +66.9% |
| 3 months ago | $5.67 | $1,130.51 | +13.1% |
| 6 months ago | $6.14 | $1,043.97 | +4.4% |
| 1 year ago | $3.25 | $1,972.31 | +97.2% |
| All time (5.0y) ago | $92 | $69.67 | -93.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMDX forecast.
Our base-case forecast reaches $13.00 around 2030.
Implied market cap at $13.00: $419.77M
Longer-term, the forecast shows a sustained bullish trajectory with annualized growth in the average price from 2029 through 2050. 2029 carries an avg of $10.57 (min $6.80, max $17.72; ROI 73.5; sentiment BULLISH), followed by 2030 with an avg of $11.63 (min $7.15, max $20.29; ROI 91; sentiment BULLISH) and 2031 with an avg of $13.31 (min $7.83, max $24.02; ROI 118.6; sentiment BULLISH).
The path continues to 2032 with an avg of $13.55 (min $7.64, max $25.20; ROI 122.5; sentiment BULLISH), and 2033 with an avg of $12.47 (min $6.75, max $23.82; ROI 104.7; sentiment BULLISH). By 2034 the avg is $14.08 (min $7.33, max $27.57; ROI 131.2; sentiment BULLISH) and 2035 with an avg of $17.62 (min $8.83, max $35.29; ROI 189.3; sentiment BULLISH).
The bullish theme strengthens into 2040 with an avg of $22.56 (min $10.15, max $49.64; ROI 270.5; sentiment BULLISH), and culminates in 2050 with an avg of $55.36 (min $24.91, max $127.34; ROI 809.1; sentiment BULLISH). These figures illustrate a long-run value upside, albeit with notable year-to-year volatility and uncertainty inherent in stock price forecasts.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $11.63 with a min of $7.15 and a max of $20.29, corresponding to an ROI of 91% and a bullish sentiment.
Forecasts indicate a bullish trend emerging from 2029 onward, with rising averages and a high-long horizon (2050 avg $55.36; max $127.34; ROI 809.1). These are estimates, not guarantees, and should be weighed against risk and individual circumstances.
Yes. The 2050 forecast lists an average price of $55.36 and a maximum of $127.34, implying potential to surpass $50 under the modeled outcomes.
Current price is $6.09 and market capitalization is $196.65M, with a market rank of 3859.
The 30-day range spans from $3.91 to $9.48, with near-term support at $3.00 and resistance at $6.42.
Insight Molecular Diagnostics Inc. Community Discussion
0Share your Insight Molecular Diagnostics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.